NKCx Histopathological outcome* within 12 months after cervix cytology in 2016
431 Helsingborg

  Benign CIN1 CIN2 CIN3 AIS Cancer Other PAD missing Total
Cytology Count Pct Count Pct Count Pct Count Pct Antal Andel Count Pct Count Pct Count Pct Count Pct
Benign sample 400 2.2% 17 0.1% 4 0.0% 10 0.1% 1 0.0% 1 0.0% 33 0.2% 18111 97.5% 18577 100.0%
ASCUS 123 17.0% 79 10.9% 10 1.4% 35 4.8% . . . . 36 5.0% 441 60.9% 724 100.0%
CIN1 89 22.3% 82 20.6% 22 5.5% 45 11.3% . . . . 27 6.8% 134 33.6% 399 100.0%
Atypical glandular cells/AGC 8 47.1% 1 5.9% . . . . 2 11.8% 2 11.8% . . 4 23.5% 17 100.0%
Unclear atypia 3 15.0% 3 15.0% . . 5 25.0% 2 10.0% 1 5.0% 2 10.0% 4 20.0% 20 100.0%
ASC-H 3 5.8% 15 28.8% 4 7.7% 23 44.2% . . 1 1.9% 5 9.6% 1 1.9% 52 100.0%
CIN2 8 4.5% 18 10.1% 54 30.3% 90 50.6% 1 0.6% 1 0.6% . . 6 3.4% 178 100.0%
CIN3 2 2.4% . . 5 6.0% 72 86.7% . . 2 2.4% . . 2 2.4% 83 100.0%
Adenocarcinoma 1 12.5% . . . . . . 1 12.5% 2 25.0% . . 4 50.0% 8 100.0%
Malignant tumor with unclear origin . . . . . . . . . . 1 33.3% 1 33.3% 1 33.3% 3 100.0%
Squamous cell cancer . . . . . . . . . . 6 85.7% . . 1 14.3% 7 100.0%
Total 637 3.2% 215 1.1% 99 0.5% 280 1.4% 7 0.0% 17 0.1% 104 0.5% 18709 93.2% 20068 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (CIN1) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M80203, M80703, M81403, M84413, M84416